Showing 2 results for Dehbanpour
Zahra Shaghaghi, Maryam Alvandi, Soghra Farzipour, Fereshteh Talebpour Amiri, Mohammadreza Dehbanpour,
Volume 32, Issue 213 (10-2022)
Abstract
Cancer is one of the most difficult diseases to treat in modern medicine. Annually, many articles are published that propose various ways for preventing carcinogenesis. Furthermore, research into cancer treatments is carried out with minimal side effects. The most common non-invasive cancer treatments include chemotherapy, targeted therapy, radiotherapy, and immunotherapy. Low effectiveness of chemo-radiation therapy and normal tissue toxicity caused by these treatments are two of the most difficult challenges. Some medicines have been recommended as adjuvants to increase tumor responses while also reducing normal tissue damage. Cerium oxide as a nanoparticle (nanoceria, CNPs) has recieved a lot of interest as a way to control tumor and normal tissue responses to various cancer treatment regimens. In vitro and in vivo studies demonstrate that it can reduce chemo-radiation toxicity in normal tissues as an antioxidant and anti-inflammatory agent. Furthermore, it has the ability to make cancer cells more sensitive to both chemotherapy and radiotherapy. In this paper, we reviewed the potential role of nanoceria for preserving normal tissues and sensitization of cancer cells in combination with different cancer treatment modalities.
Maryam Alvandi, Zahra Shaghaghi, Mohammad Reza Dehbanpour, Soghra Farzipour, Fereshteh Talebpour Amiri,
Volume 32, Issue 217 (1-2023)
Abstract
Radiation therapy is one of the major subsets of cancer treatments. Normal tissue toxicity and tumor cell resistance are two main obstacles during radiotherapy treatments. Toxicity to healthy tissue limits the applied dose, resulting in inadequate tumor control. On the other hand, the resistances of cancer cells lead to increased doses of radiotherapy. Therefore, agents that can simultaneously reduce the toxicity of normal tissues and increase the sensitivity of tumor cells to radiotherapy could be a potential solution to increase the efficiency of radiotherapy during cancer treatment. Many studies have found that atorvastatin, as an HMG coenzyme A reductase (HMG-CoA) inhibitor, and protects normal tissue while sensitizing cancer cells to radiotherapy via various molecular mechanisms and signaling pathways. This review summarizes the evidence for radioprotective and radiosensitivity effects of atorvastatin in vitro and in vivo studies.
